Compare Stocks: TCRT, PYXS, MDWD, and PLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$14.30 +0.6%	$14.43	$13.54 ▼ $20.30	$183.78M	0.14	93,614 shs	66,885 shs
PLX Protalix BioTherapeutics	$2.37 +2.2%	$2.22	$1.41 ▼ $3.19	$190.96M	N/A	945,735 shs	716,114 shs
PYXS Pyxis Oncology	$3.16 +3.9%	$2.28	$0.97 ▼ $5.55	$200.19M	1.31	771,987 shs	925,724 shs
TCRT Alaunos Therapeutics	$1.90 -0.3%	$2.19	$1.67 ▼ $4.59	$46.40M	-1	17,175 shs	6,537 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	+0.71%	-1.59%	-6.20%	-18.46%	-23.26%
PLX Protalix BioTherapeutics	-2.11%	-3.33%	0.00%	+18.37%	+60.00%
PYXS Pyxis Oncology	+14.72%	+4.47%	+15.59%	+66.12%	+176.36%
TCRT Alaunos Therapeutics	+1.33%	-1.30%	-8.41%	-27.01%	-30.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$14.30 +0.6%	$14.43	$13.54 ▼ $20.30	$183.78M	0.14	93,614 shs	66,885 shs
PLX Protalix BioTherapeutics	$2.37 +2.2%	$2.22	$1.41 ▼ $3.19	$190.96M	N/A	945,735 shs	716,114 shs
PYXS Pyxis Oncology	$3.16 +3.9%	$2.28	$0.97 ▼ $5.55	$200.19M	1.31	771,987 shs	925,724 shs
TCRT Alaunos Therapeutics	$1.90 -0.3%	$2.19	$1.67 ▼ $4.59	$46.40M	-1	17,175 shs	6,537 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	+0.71%	-1.59%	-6.20%	-18.46%	-23.26%
PLX Protalix BioTherapeutics	-2.11%	-3.33%	0.00%	+18.37%	+60.00%
PYXS Pyxis Oncology	+14.72%	+4.47%	+15.59%	+66.12%	+176.36%
TCRT Alaunos Therapeutics	+1.33%	-1.30%	-8.41%	-27.01%	-30.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDWD MediWound	2.25	Hold	$34.00	137.76% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	406.33% Upside
PYXS Pyxis Oncology	2.70	Moderate Buy	$7.50	137.34% Upside
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRT, PYXS, MDWD, and PLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
8/3/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	PYXS Pyxis Oncology	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$9.00 ➝ $7.00
6/30/2026	PYXS Pyxis Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/5/2026	PYXS Pyxis Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/29/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/28/2026	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
5/27/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $32.00
5/21/2026	PYXS Pyxis Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDWD MediWound	$14.48M	12.69	N/A	N/A	$3.40 per share	4.21
PLX Protalix BioTherapeutics	$76.38M	2.50	$0.13 per share	17.80	$0.47 per share	5.04
PYXS Pyxis Oncology	$13.86M	14.44	N/A	N/A	$0.86 per share	3.67
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	$0.93 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDWD MediWound	-$23.88M	-$2.26	N/A	N/A	N/A	-180.30%	-67.22%	-31.87%	8/13/2026 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.18	N/A	7.65	N/A	-21.03%	-30.89%	-11.74%	N/A
PYXS Pyxis Oncology	-$79.62M	-$1.31	N/A	N/A	N/A	N/A	-135.60%	-85.00%	8/13/2026 (Estimated)
TCRT Alaunos Therapeutics	-$4.18M	-$2.13	N/A	N/A	N/A	N/A	-165.94%	-123.50%	8/18/2026 (Estimated)

Latest TCRT, PYXS, MDWD, and PLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MDWD MediWound	-$0.76	N/A	N/A	N/A	$2.59 million	N/A
8/13/2026	Q2 2026	PYXS Pyxis Oncology	-$0.34	N/A	N/A	N/A	$0.03 million	N/A
5/27/2026	Q1 2026	MDWD MediWound	-$0.65	-$0.23	+$0.42	-$0.23	$3.37 million	$1.48 million
5/15/2026	Q1 2026	TCRT Alaunos Therapeutics	N/A	-$0.59	N/A	-$0.59	N/A	N/A
5/14/2026	Q1 2026	PYXS Pyxis Oncology	-$0.35	-$0.37	-$0.02	-$0.37	$0.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDWD MediWound	N/A	2.41	2.19
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PYXS Pyxis Oncology	N/A	2.76	2.76
TCRT Alaunos Therapeutics	N/A	1.63	1.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDWD MediWound	46.83%
PLX Protalix BioTherapeutics	16.53%
PYXS Pyxis Oncology	39.07%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
MDWD MediWound	9.20%
PLX Protalix BioTherapeutics	6.70%
PYXS Pyxis Oncology	5.70%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDWD MediWound	80	12.85 million	11.67 million	Optionable
PLX Protalix BioTherapeutics	200	80.57 million	69.00 million	Optionable
PYXS Pyxis Oncology	60	63.35 million	59.74 million	Optionable
TCRT Alaunos Therapeutics	40	24.42 million	20.48 million	No Data

TCRT, PYXS, MDWD, and PLX Headlines

Recent News About These Companies

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026 | markets.businessinsider.com

Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | finanznachrichten.de

Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers

May 26, 2026 | msn.com

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | globenewswire.com

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026 | globenewswire.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

Alaunos Reports Positive Preclinical Data for Obesity Candidate

March 2, 2026 | tipranks.com

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026 | globenewswire.com

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

December 23, 2025 | tipranks.com

Alaunos Therapeutics files to sell 327,740 shares of common for holders

October 22, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, PYXS, MDWD, and PLX Company Descriptions

MediWound NASDAQ:MDWD

$14.30 +0.08 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$14.28 -0.02 (-0.10%)

As of 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Protalix BioTherapeutics NYSE:PLX

$2.37 +0.05 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 0.00 (-0.21%)

As of 04:10 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Pyxis Oncology NASDAQ:PYXS

$3.16 +0.12 (+3.95%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 +0.01 (+0.47%)

As of 04:33 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Alaunos Therapeutics NASDAQ:TCRT

$1.90 -0.01 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 +0.08 (+3.95%)

As of 04:10 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, PYXS, MDWD, and PLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, PYXS, MDWD, and PLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, PYXS, MDWD, and PLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, PYXS, MDWD, and PLX Company Descriptions

MediWound NASDAQ:MDWD

Protalix BioTherapeutics NYSE:PLX

Pyxis Oncology NASDAQ:PYXS

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, PYXS, MDWD, and PLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, PYXS, MDWD, and PLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, PYXS, MDWD, and PLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, PYXS, MDWD, and PLX Company Descriptions

MediWound NASDAQ:MDWD

Protalix BioTherapeutics NYSE:PLX

Pyxis Oncology NASDAQ:PYXS

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools